Joseph M. Sanzari Children’s Hospital Shows PET Value in Pediatric Nodular Lymphocyte-Predominant Hodgkin Lymphoma Outcomes

Children’s Oncology Group study addresses lack of published data on PET use in patients with nLPHL

As part of a Children’s Oncology Group study, researchers at Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center have shown that PET response following three cycles of chemotherapy was highly predictive of outcome in pediatric patients with low-risk nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL).

Positron emission tomography (PET) plays an important role in staging and assessing treatment response in classic Hodgkin lymphoma, but little had been published prior regarding its use in patients with nLPHL. By providing better understanding of the clinical significance of PET results in nLPHL, this research opens the possibility of using PET in future nLPHL trials.

The study also confirmed that intermediate-risk patients with a negative PET following chemotherapy achieved excellent outcomes.

The study was presented at the American Society of Hematology annual meeting.

Learn more about innovative pediatric cancer care at Hackensack Meridian Children's Health.